- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Dr. Anthony on Treatment Benefit With Telotristat Epitrate in Patients With Carcinoid Syndrome
Lowell B. Anthony, MD, professor of Medicine, University of Kentucky, discusses patient exit interviews from the phase III placebo-controlled TELESTAR trial, which evaluated telotristate epitrate in patients with inadequately controlled carcinoid syndrome.
Lowell B. Anthony, MD, professor of Medicine, University of Kentucky, discusses patient exit interviews from the phase III placebo-controlled TELESTAR trial, which evaluated telotristate epitrate in patients with inadequately controlled carcinoid syndrome.
The prospective, randomized, placebo-controlled trial enrolled more than 100 patients, 35 of which participated in exit interviews from the randomized treatment portion of TELESTAR prior to going on the open-label study.
Patients reported symptoms mainly consisting of diarrhea and the frequency of it, physical function, and impact these symptoms had on their quality of life. A total of 33 of the 35 patients participated in interviews, one-third of which were on placebo. Fourtee patients did not report any signs of improvement, 7 patients had somewhat improvement, and 12 had definite improvement. The reduction in diarrhea allowed for better quality of life, Anthony adds.
<<<